Biotechnology

• 

  Subject Areas on Research

  • 1028. Use of Antisense Oligonucleotides To Restore Activity in Mutant p53 
  • 104. Role of the HI Loop in the Adeno- Associated Virus (AAV) Life Cycle 
  • 1064. Haute Couture Vectors: Solving Clinical Problems with Custom Designed AAV Vectors 
  • 1088. Stem Cell Gene Therapy with No Pre-Conditioning for the ADA-Deficiency Patients Leads to Generalized Detoxification and Delayed, but Steady Hematological Reconstitution 
  • 14. Next Generation AAV Vectors for Limiting Systemic Leakage and Improving Safety Following CNS Administration 
  • 167. Genome Editing to Generate the First Mouse Model of Alpha-One Antitrypsin Deficiency, the Leading Cause of Genetic COPD 
  • 2'-Deoxy-2'-fluoro-arabinonucleic acid: a valid alternative to DNA for biotechnological applications using charge transport. 
  • 211. Development of Helper-Dependent Adenovirus (HDAd) Vectors for Gene Therapy in the Mouse Model for Glycogen Storage Disease Type Ia (GSD-Ia) 
  • 219. Persistent Correction of Hyperphenylalaninemia Following Liver-Directed, rAAV2/8-Mediated Gene Therapy for Murine Phenylketonuria (PKU) 
  • 258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV) 
  • 265. Polysialic Acid as a Novel Regulator of AAV Tropism in the Developing Brain 
  • 30. Modulation of Intracellular Calcium Enhances AAV Transduction in the CNS 
  • 30. Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID) Using a γ-Retroviral Vector 
  • 302. Combinatorial Engineering of a Receptor Footprint on AAV Serotype 4 Yields Novel Vectors 
  • 311. In Vivo Zinc Finger Nuclease-Mediated Targeted Integration of a Glucose-6-Phosphatase Transgene Enhances Biochemical Correction in Mice with Glycogen Storage Disease Type IA 
  • 339. Sustained, High-Level Expression of Human Acid Alpha-Glucosidase and Correction of Glycogen Storage Disease Type II (GSD II) with an Adeno-Associated Virus 8 (AAV2/8) Vector Containing a Liver-Specific Promoter 
  • 38. Pharmacological Regulation of Vesicular Trafficking as a Strategy to Enhance Recombinant AAV Transduction 
  • 381. Prohypertrophic Agents Enhance the Response to Gene Therapy in Pompe Disease 
  • 397. Correction of the Dystrophin Gene By the CRISPR/Cas9 System in a Mouse Model of Muscular Dystrophy 
  • 41. U2 snRNP Spliceosome Proteins Block Recombinant AAV Vector Transduction 
  • 42. Differential Transduction Profiles of AAV Vectors in a Mouse Model of Human Glycosylation 
  • 425. Translation of Enhanced Dendritic Cell Vaccines Using a CID-Inducible CD40 Receptor 
  • 427. Adenovirus Mediated GRP94/gp96 Expression in Treatment of Neuroblastoma 
  • 472. Low-Shear Sodding of an Implantable Expanded Polytetrafluoroethylene Scaffold with a Rat Adipose-Derived Stromal-Vascular Fraction 
  • 482. Local and Systemic Gene Editing in a Mouse Model of Duchenne Muscular Dystrophy 
  • 485. Targeted Epigenome Editing by CRISPR/Cas9-Based Repressors for Silencing of Distal Regulatory Elements 
  • 487. Liver-Targeted Gene Therapy in Glycogen Storage Disease Type Ia (GSD-Ia) Requires Widespread, Regulated Glucose-6-phosphatase 
  • 49. Minimum Effective Dose of Liver-Targeted Gene Therapy for Pompe Disease Reduced 10-Fold from Prior Estimates 
  • 5 ' exon replacement by spliceosome mediated RNA trans-splicing 
  • 504. Restoration of Dystrophin Expression by Gene Editing with S. aureus Cas9 in Models of Duchenne Muscular Dystrophy 
  • 563. Correction of Glycogen Storage Disease Type II by Systemic Delivery of an AAV2/8 Vector Containing a Muscle-Specific Promoter 
  • 586. Anti-HIV-1 Neutralizing Antibody Gene Delivery to Rhesus Macaques and Rodents: A Novel Vaccination Approach 
  • 59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype 
  • 61. Vascular Smooth Muscle Cell RNA Aptamers for the Treatment of Cardiovascular Disease 
  • 66. Identification and Characterization of a B Cell Aptamer That Targets Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Myelogenous Leukemia (CML) 
  • 7. Adeno-Associated Virus Type 2 (AAV2) Contains an Integrin alpha5beta1 Recognition Sequence Essential for Viral Cell Entry 
  • 701. Long-Term Complications of Glycogen Storage Disease Type IA in the Dog Model Treated With Gene Replacement Therapy 
  • 727. Characterizing the Adeno-Associated Virus 1 Sialic Receptor Binding Site and Its Overlap with Antigenic Epitopes 
  • 739. Bioluminescent Virion Shells: A Novel Tool for Visualization of Viral Vectors in Animal Tissue 
  • 8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction 
  • 83. Cell_Type Specific Delivery of siRNAs with Aptamer_siRNA Chimeras 
  • 93. Development of AAVidua Vector for the Treatment of Cornea Associated Vision Loss in Bone Marrow Treated-Hurler Patients 
  • 954. High Intensity Focused Ultrasound (HIFU) Induced Trans-Gene Activation in Solid Tumors 
  • A Beautiful Mind and the Heart of an Explorer 
  • A CRISPR Screen Identifies Apical Polarity Determinant Crumbs 3 as an AAV Host Restriction Factor 
  • A CRISPR/Cas9 Genome Wide Screen and Cryo-EM Structure Reveal Receptor Switching by a Synthetic AAV Variant 
  • A CRISPRa Screen Identifies Transcription Factors That Can Silence or Activate rAAV Genomes 
  • A Combination Immunosuppression Treatment with Bortezomib and an Anti-CD20 mAb Enables Successful Re-Administration of AAV8 Vector in Mice 
  • A Human iPSC-Derived Neuron and Cardiomyocyte Platform for Assessing Novel Recombinant Adeno-Associated Viral (AAV) Vectors 
  • A Newly Evolved AAV Variant Enables Potent Gene Transfer in Kidneys of Multiple Species 
  • A Novel Approach for Rapid and Transient Depletion of Pre-Existing Neutralizing Antibodies Against AAV Vectors 
  • A Novel Aptamer Targeting Agent for Prostate Cancer 
  • A Novel Capsid for Smooth Muscle Pathology in Pompe Disease 
  • A Novel Human Liver Chimeric Mouse Model Lacking the Murine AAVR Gene for Validation of AAV Gene Therapy Vectors 
  • A Single Intravenous Injection of an AAV-PHP. B Vector Encoding Human Acid alpha-Glucosidase Corrects Both Muscle and Brain Defects in Murine Pompe Disease 
  • A Status Report on FDA Approval of Medical Devices Containing Nanostructured Materials. 
  • A central role of RNA in developing therapeutic vaccines for cancer and infectious diseases 
  • A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34+ cells 
  • A cone-plate apparatus for the in vitro biochemical and molecular analysis of the effect of shear stress on adherent cells 
  • A cornucopia of strategies for the immunotherapy of cancer 
  • A genetically engineered plasmid encoding a zinc finger VEGF-activating transcription factor induces angiogenesis in the rabbits with hind-limb ischemia 
  • A kinetic analysis using fractals of cellular analyte-receptor binding and dissociation. 
  • A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. 
  • A method for the organ explant culture of fish kidney tubules 
  • A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors. 
  • A model for optimizing adenoviral delivery in human cancer gene therapy trials. 
  • A need for effective adjuvants. 
  • A new non-enzymatic method for isolating human intervertebral disc cells preserves the phenotype of nucleus pulposus cells. 
  • A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. 
  • A novel conditionally replicating "armed" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling. 
  • A novel thermostable branching enzyme from an extremely thermophilic bacterial species, Rhodothermus obamensis. 
  • A numerical analysis of forces exerted by laminar flow on spreading cells in a parallel plate flow chamber assay. 
  • A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. 
  • A physical characterization of GAP A3 hybridoma cells: morphology, geometry, and mechanical properties. 
  • A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. 
  • A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. 
  • A roadmap for interpreting (13)C metabolite labeling patterns from cells. 
  • A small regulatory element from chromosome 19 enhances liver-specific gene expression. 
  • A synthetic biology challenge: making cells compute. 
  • A tumour specific targeted radiotherapy/gene therapy for the treatment of malignant disease 
  • A year of successful cancer vaccines points to a path forward. 
  • AAV Capsid Dynamics at the 5-Fold Pore Controls Genome Release 
  • AAV Gene Therapy Effectively Transduces the Central Nervous System and Prevents Polyglucosan Body Formation in Adult Polyglucosan Body Disease Mice 
  • AAV Gene Therapy in a Canine Model of MPS1 Prevents and Reverses Corneal Blindness 
  • AAV Hijacks Cellular Secretion Machinery for Efficient Viral Egress 
  • AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. 
  • AAV-CNS matters turn from gray to white. 
  • AAV-Mediated Deletion of a Large Mutational Hotspot for Treatment of Duchenne Muscular Dystrophy 
  • AAV-Mediated Gene Therapy Using a Novel Dual Promoter Prevents Pullulanase-Induced Cytotoxic T Lymphocyte Response and Corrects Major Affected Tissues in GSD IIIa Mice 
  • AAV-Mediated Gene Therapy for Glycogen Storage Disease Type III Using a Bacterial Glycogen Debranching Enzyme 
  • AAV-MediatedTAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome 
  • AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice. 
  • APOE-Targeted Epigenome Therapy for Alzheimer's Disease 
  • Activity of carbonic anhydrase immobilized on porous silica beads in organic media 
  • Adeno-Associated Virus Capsid-Promoter Interactions in the Brain Translate from Rat to the Nonhuman Primate. 
  • Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, Atp1a3Mashl/+, Mouse Model of Alternating Hemiplegia of Childhood. 
  • Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. 
  • Adeno-associated virus serotypes: vector toolkit for human gene therapy. 
  • Adeno-associated virus-mediated gene therapy for metabolic myopathy. 
  • Adenovirus-mediated gene transfer of the beta2-adrenergic receptor to donor hearts enhances cardiac function. 
  • Adhesion mediated by bonds in series. 
  • Adjunctive beta 2-Agonist Therapy Enhances Trafficking of Acid alpha-Glucosidase to Lysosomes in the Skeletal Muscle of Mice with Pompe Disease 
  • Advances in our understanding of ligand-activated nuclear receptors 
  • Advances in pharmacogenomic research and development. 
  • Advances in quantitative UV-visible spectroscopy for clinical and pre-clinical application in cancer. 
  • Advances in targeted genome editing. 
  • Advancing islet transplantation: from engraftment to the immune response. 
  • Allele Specific Knockdown of APOE e4 Expression: A Novel Platform for Precision Gene Therapy in Alzheimer's Disease 
  • Alterations of endophytic microbial community function in Spartina alterniflora as a result of crude oil exposure. 
  • Altered distribution of mitochondria and actin fibers in 3T3 cells cultured on microcarriers. 
  • Altering Tissue Glycan Patterns Improves the Transduction Profile of AAV9 Vectors 
  • Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. 
  • An Endogenous TNF-α Antagonist Induced by Splice-switching Oligonucleotides Reduces Inflammation in Hepatitis and Arthritis Mouse Models. 
  • An Isogenic hiPSC-Derived Model System for Establishing Gene Therapy Approaches in Alzheimer's Disease 
  • An autonomously self-assembling dendritic DNA nanostructure for target DNA detection. 
  • An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. 
  • An emerging adeno-associated viral vector pipeline for cardiac gene therapy. 
  • An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. 
  • An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies. 
  • Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. 
  • Analysis of neuronal proliferation, migration and differentiation in the postnatal brain using equine infectious anemia virus-based lentiviral vectors. 
  • Analysis of oxygen transport in a diffusion-limited model of engineered heart tissue. 
  • Analysis of the rate-limiting step of an anaerobic biotrickling filter removing TCE vapors 
  • Anti-cryptococcal activity of preussolides A and B, phosphoethanolamine-substituted 24-membered macrolides, and leptosin C from coprophilous isolates of Preussia typharum. 
  • Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. 
  • Antibody-antigen binding kinetics. A model for multivalency antibodies for large antigen systems. 
  • Antidote control of aptamer therapeutics: the road to a safer class of drug agents. 
  • Antisettlement and Narcotic Action of Analogues of Diterpene Marine Natural Product Antifoulants from Octocorals. 
  • Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro. 
  • Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system: effects on yield. 
  • Application of a moving bed biofilm reactor for tertiary ammonia treatment in high temperature industrial wastewater. 
  • Application of an antibody biochip for p53 detection and cancer diagnosis. 
  • Applications of nanotechnology to biotechnology commentary. 
  • Approaches to HIV vaccine design. 
  • Aptamer-siRNA Chimera Inhibitors of Intimal Hyperplasia 
  • Aptamers in immunotherapy. 
  • Aquaporins and CSF Flux Are Critical Determinants of AAV Mediated CNS Gene Transfer 
  • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. 
  • Bacterial removal of mercury from sewage. 
  • Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. 
  • Bezafibrate Enhances AAV Gene Therapy in Glycogen Storage Disease Type Ia 
  • Bimodular CRISPR/Cas-lentiviral Vector for Modeling Diseases 
  • Bioactive poly(ethylene glycol) hydrogels to recapitulate the HSC niche and facilitate HSC expansion in culture. 
  • Biocatalytic coatings for air pollution control: a proof of concept study on VOC biodegradation. 
  • Biochemical, morphological, and genetic variations in Microcystis aeruginosa due to colony disaggregation 
  • Bioengineered Skeletal Muscle With Functional Stem Cell Pool and Capacity for Vascular Integration and Maturation In Vivo 
  • Biological function made crystal clear - annotation of hypothetical proteins via structural genomics. 
  • Biological waste air treatment in biofilters. 
  • Biological waste air treatment in biotrickling filters 
  • Biology by design: reduction and synthesis of cellular components and behaviour. 
  • Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. 
  • Biomass control in waste air biotrickling filters by protozoan predation. 
  • Biomaterializing the promise of cardiac tissue engineering. 
  • Biomechanics of vascular-stent interaction and in-stent restenosis: The key role of shear stress 
  • Biomedical implications of protein folding and misfolding. 
  • Biotreatment of groundwater contaminated with MTBE: interaction of common environmental co-contaminants. 
  • Boosting, Not Breaking: CRISPR Activators Treat Disease Models. 
  • Breast cancer: integrating the patient with her genome. 
  • CRISPR-Mediated Gene Correction in a Severe Humanized Mouse Model of Duchenne Muscular Dystrophy 
  • CRISPR-based methods for high-throughput annotation of regulatory DNA. 
  • CRISPR/Cas9 Inducible Systems for Neurodegenerative Disease 
  • CRISPR/Cas9-Based Transcriptional Repressors for Control of Human Gene Expression 
  • Capsid-Glycan Receptor Interactions Influence AAV Transport across the Blood-Brain Barrier 
  • Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. 
  • Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. 
  • Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. 
  • Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. 
  • Cell population dynamics model for deconvolution of murine embryonic stem cell self-renewal and differentiation responses to cytokines and extracellular matrix. 
  • Cell-Targeted RNA-Based Therapies for Cardiovascular Disease 
  • Cellular arrays for large-scale analysis of transcription factor activity. 
  • Cellular uptake of neutral phosphorodiamidate morpholino oligomers. 
  • Centrifugation without a balance tube 
  • Centromere round-up at the heterochromatin corral. 
  • Characterization of Clostridium ljungdahlii OTA1: a non-autotrophic hyper ethanol-producing strain. 
  • Characterization of Liver Pathology in a Novel GSD IX y2 Mouse Model 
  • Characterization of bimodal cell death of insect cells in a rotating- wall vessel and shaker flask 
  • Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. 
  • Characterizing Essential Receptor Binding Residues for AAV1 
  • Clinical applications of dendritic cell vaccines. 
  • Co-opting biology to deliver drugs. 
  • Colloidal gold as a biocompatible immobilization matrix suitable for the fabrication of enzyme electrodes by electrodeposition. 
  • Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. 
  • Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. 
  • Comparative genomics as a tool for gene discovery. 
  • Comparing genome editing technologies 
  • Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections. 
  • Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. 
  • Computational Fluid Dynamics and Additive Manufacturing to Diagnose and Treat Cardiovascular Disease. 
  • Computing. Successes and challenges. 
  • Conspecific cues that induce spore settlement in the biofouling and green tide-forming alga Ulva tepida provide a potential aggregation mechanism 
  • Continuous operation of foamed emulsion bioreactors treating toluene vapors. 
  • Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. 
  • Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. 
  • Correction of Glycogen Storage Disease Type III with an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme 
  • Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases 
  • Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. 
  • Correction of glycogen storage disease type II (GSD II) by intramuscular administration of an adeno-associated virus (AAV) vector pseudotyped as AAV6 
  • Correction of glycogen storage disease type II (GSD II) with an adeno-associated virus 8 (AAV2/8) vector 
  • Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. 
  • Correction of glycogen storage disease type II by intramuscular administration of an adeno-associated virus 6 (AAV2/6) vector containing a muscle-specific promoter 
  • Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. 
  • Corrective gene transfer into bone marrow CD34+cells for adenosine deaminase (ADA) deficiency: Results in four patients after one year of follow-up 
  • Corrigendum to "Efficacy of Helper-dependent Adenovirus Vector-mediated Gene Therapy in Murine Glycogen Storage Disease Type Ia". 
  • Critical assessment of gassing-in methods to determine mass transfer coefficient in miniature and microbioreactors with gas-liquid flow 
  • Critical issues in delivery of RNAi therapeutics in vivo. 
  • Cross-Species Evolution of Synthetic AAV Strains for Clinical Translation 
  • Cultivation studies on wild and hybrid strains of Pleurotus tuberregium (Fr.) Sing. on wheat straw substrate. 
  • Current technology for the derivation of pluripotent stem cell lines from human embryos. 
  • Current trends in differential expression proteomics: isotopically coded tags. 
  • D-amino acid oxidase and catalase of detergent permeabilized Rhodotorula gracilis cells and its potential use for the synthesis of α-keto acids 
  • DNA patents and diagnostics: not a pretty picture. 
  • DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. 
  • Decarbonizing agriculture through the conversion of animal manure to dietary protein and ammonia fertilizer. 
  • Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to Adeno-Associated Virus Vector Containing a CMV Enhancer/Chicken beta-Actin Cassette in Murine Pompe Disease 
  • Defining Transcription Regulatory Elements in the Human Frataxin Gene: Implications for Gene Therapy. 
  • Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. 
  • Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of meeting March 8-10, 2000. 
  • Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice 
  • Desensitization through Immunomodulatory Gene Therapy Suppresses the Antibody Response to Enzyme Replacement Therapy in Murine Pompe Disease 
  • Design Principles for AAV Mediated Circular RNA Expression in the Brain 
  • Detailed investigations of dissolved hydrogen and hydrogen mass transfer in a biotrickling filter for upgrading biogas. 
  • Developing elite Neurospora crassa strains for cellulosic ethanol production using fungal breeding. 
  • Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration 
  • Development of AAV-shRNA vectors for human basal-like breast cancer therapy 
  • Development of Lentiviral Platform for Allele-Specific Targeted Down-Regulation of APOEe4 Expression: Epigenetic Therapy for Precision Medicine in Alzheimer's Disease 
  • Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. 
  • Development of a novel intravascular oxygenator catheter: Oxygen mass transfer properties across nonporous hollow fiber membranes. 
  • Development of adeno-associated virus (AAV) vectors for gene therapy in the mouse model for glycogen storage disease type Ia (GSD-Ia) 
  • Development of foamed emulsion bioreactor for air pollution control. 
  • Development of mammalian serum albumin affinity purification media by peptide phage display. 
  • Development of novel biotherapeutics for breast cancer: generation of function blocking antibodies against Notch1 ligands 
  • Diagnosis of fungal infection: new technologies for the mycology laboratory. 
  • Diamagnetic levitation changes growth, cell cycle, and gene expression of Saccharomyces cerevisiae. 
  • Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. 
  • Digital image analysis for rapid quantification of total RNA and cDNA for SMART-PCR. 
  • Digital pathology in nephrology clinical trials, research, and pathology practice. 
  • Direct Comparison of Epifluorescence and Immunostaining for Assessing Viral Mediated Gene Expression in the Primate Brain. 
  • Direct force measurements of the streptavidin-biotin interaction. 
  • Directing three-dimensional multicellular morphogenesis by self-organization of vascular mesenchymal cells in hyaluronic acid hydrogels 
  • Discontinuation of PEG-ADA replacement therapy in a patient with ADA-deficiency previously treated with retroviral-mediated, T cell-directed gene therapy 
  • Discovery of a Neurotropic Footprint That Enables AAV Transport Across the Blood-Brain Barrier 
  • Disruption of Water Homeostasis Affects AAV Transport Across the Blood-Brain Barrier 
  • Distinct Functional Roles for AAV Capsid Surface Epitopes Revealed through Structure-Guided Evolution 
  • Downregulation of SNCA Expression as a Therapoetic Approach for Parkinson's Disease and Other Synucleinopathies: New Target Validation for Next-Generation Drug Discovery 
  • Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD. 
  • Drag reducing properties of microalgal exopolymers. 
  • Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. 
  • Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. Aureus Cas9 
  • Dystrophin Restoration in a Humanized Mouse Model of Duchenne Muscular Dystrophy by Gene Editing with S. aureus Cas9 
  • EZH2 RIP-seq Identifies Tissue-specific Long Non-coding RNAs. 
  • Early marine bacterial biofilm on a copper-based antifouling paint 
  • Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. 
  • Editing out Five SERPINA1 Paralogs to Create a New Mouse Model of Genetic Emphysema 
  • Editorial overview - A cornucopia of strategies for the immunotherapy of cancer 
  • Editorial overview - A need for effective adjuvants 
  • Editorial overview: Fulfilling the promise of immunotherapy 
  • Editorial overview: Priming, boosting, measuring 
  • Editorial overview: What is a vaccine? 
  • Effect of AAV Gene Therapy on Hepatic Tumor Induced by Deficiency of Glucose-6-Phosphatase 
  • Effect of carbon source addition on toluene biodegradation by an Escherichia coli DH5alpha transconjugant harboring the TOL plasmid. 
  • Effect of genetic circular permutation near the active site on the activity and stability of an enzyme inhibitor. 
  • Effect of streptavidin RGD mutant on the adhesion of endothelial cells. 
  • Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. 
  • Effects of medical research on health care and economy. 
  • Effects of unsteady state conditions on the biooxidation of methyl ethyl and methyl isobutyl ketone in continuous flow liquid phase cultures 
  • Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease. 
  • Efficacy of Genome Editing in Infant Mice with Glycogen Storage Disease Type Ia 
  • Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. 
  • Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. 
  • Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. 
  • Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. 
  • Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. 
  • Electron capture dissociation mass spectrometry in characterization of peptides and proteins. 
  • Emerging strategies for engineering microbial communities. 
  • Enabling Technologies for Personalized and Precision Medicine. 
  • Endophytic Phytoaugmentation: Treating Wastewater and Runoff Through Augmented Phytoremediation. 
  • Energy biotechnology in 2013: advanced technology development for breakthroughs in fuels and chemicals production. 
  • Engineered cell-cell communication and its applications. 
  • Engineered microbial consortia: strategies and applications. 
  • Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. 
  • Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. 
  • Engineered transcription factors for therapeutic angiogenesis. 
  • Engineering A Humanized AAV8 Capsid through Iterative Structure-Guided Evolution 
  • Engineering Backsplicing Introns for Robust Expression of Synthetic Circular RNAs from AAV Vectors 
  • Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. 
  • Engineering clustered ligand binding into nonviral vectors: αvβ3 targeting as an example 
  • Engineering life: building a fab for biology. 
  • Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. 
  • Engineering microbial consortia: a new frontier in synthetic biology. 
  • Engineering microbial systems to explore ecological and evolutionary dynamics. 
  • Engineering multicellular systems by cell-cell communication. 
  • Engineering skeletal muscle repair. 
  • Engineering superficial zone features in tissue engineered cartilage. 
  • Enhanced AAV vector transduction through genetic and pharmacological inhibition of U2 snRNP components 
  • Enhanced CRISPR/Cas9 Genome Editing in Heart and Skeletal Muscle with a Potent New AAV Variant 
  • Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. 
  • Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. 
  • Enhanced oncolytic virotherapy through oxidative stress inhibition. 
  • Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. 
  • Enhancement of targeted radiotherapy in neuroblastoma: a novel gene therapy approach 
  • Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. 
  • Enhancing immunogenicity by CpG DNA. 
  • Enzymatic RNA molecules 
  • Enzymatic deglycosylation of enfumafungin, a triterpene glycoside natural product, and its chemically synthesized analogues 
  • Epigenetic Downregulation of ApoE4 for Alzheimer's Disease 
  • Epigenome-Base Strategies for Efficient and Safe Editing of APOE epsilon 4 Allele: Implications for Alzheimer's Disease 
  • Erratum to Analysis of the rate-limiting step of an anaerobic biotrickling filter removing TCE vapors, [Process Biochem. (2010), 45, 549-555] 
  • Erratum: Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia (Gene Therapy (2006) vol. 13 (1281-1289) 10.1038/sj.gt.3302774) 
  • Erratum: Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia (Gene Therapy (2006) vol. 13 (1281-1289) 10.1038/sj.gt.3302774)) 
  • Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111) 
  • Ethics for the pediatrician: a brave new pediatrics? Managing the desire for better children through biotechnological enhancement. 
  • Evaluating the mycostimulation potential of select carbon amendments for the degradation of a model PAH by an ascomycete strain enriched from a superfund site. 
  • Evaluating whole transcriptome amplification for gene profiling experiments using RNA-Seq 
  • Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model. 
  • Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. 
  • Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor 
  • Evolving New AAV Strains that Demonstrate AAVR Independence 
  • Evolving Synthetic AAV Variants for Genome Editing in Immune Cell Populations 
  • Ex Vivo Gene Delivery to Porcine Cardiac Allografts Using a Myocardial-Enhanced Adeno-Associated Viral Vector. 
  • Examining the behavior of crop-derived antibiotic resistance genes in anaerobic sludge batch reactors under thermophilic conditions. 
  • Exercise and health: can biotechnology confer similar benefits? 
  • Expanding the CNS Transduction Profile of AAV4 by Structure-Guided Evolution 
  • Exploring Novel Aptamer-Heparin Combinations to Improve Anticoagulation Therapy in Cardiopulmonary Bypass 
  • Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers 
  • FINDING TARGETS FOR FSH DYSTROPHY THERAPY 
  • Fibrillar peptide gels in biotechnology and biomedicine. 
  • Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy. 
  • Focused ultrasound (HIFU) induces localized enhancement of reporter gene expression in rabbit carotid artery. 
  • Formulations which increase the size of lipoplexes prevent serum-associated inhibition of transfection. 
  • From crystal structure to clinic: highlights of the Tenth International Parvovirus Workshop. 
  • From the editor: Trust and the value paradox in science. 
  • Fulfilling the promise of immunotherapy. 
  • Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. 
  • Functional advantages conferred by extracellular prokaryotic membrane vesicles. 
  • Functionality of the TOL plasmid under varying environmental conditions following conjugal transfer. 
  • Furin is a Host Factor Restricting Adeno-Associated Virus 4 Transduction 
  • G protein-coupled receptors and receptor kinases: from molecular biology to potential therapeutic applications. 
  • GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. 
  • Gene Therapy for Heart Disease Using Electrically Active Fibroblasts 
  • Gene Therapy for Modulation of T-Cell-Mediated Immune Response Provoked by Corneal Transplantation. 
  • Gene delivery through cell culture substrate adsorbed DNA complexes 
  • Gene expression and survival changes in Saccharomyces cerevisiae during suspension culture. 
  • Gene expression profiling of anticancer immune responses. 
  • Gene therapy for cardiovascular disease. 
  • Gene therapy progress and prospects: RNA aptamers. 
  • Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. 
  • Generation of recombinant adeno-associated virus vectors by a complete adenovirus-mediated approach. 
  • Generation of species cross-reactive aptamers using "toggle" SELEX. 
  • Genetic engineering of mesenchymal stem cells and its application in human disease therapy. 
  • Genetic profiling and tailored therapy in asthma: are we there yet? 
  • Genetic studies: look no further than your own backyard. 
  • Genetically encoded elastin-like polypeptide nanoparticles for drug delivery. 
  • Genome Editing in a Canine Model for Glycogen Storage Disease Type Ia 
  • Genome-editing Technologies for Gene and Cell Therapy. 
  • Genomics-based anti-cancer drug discovery - Preface 
  • Glyco-engineering in Archaea: differential N-glycosylation of the S-layer glycoprotein in a transformed Haloferax volcanii strain. 
  • Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. 
  • Granular hydrogels: emergent properties of jammed hydrogel microparticles and their applications in tissue repair and regeneration. 
  • Grazing scar characteristics impact degree of fungal facilitation in spartina alterniflora leaves in a south american salt marsh 
  • Group I intron-mediated trans-splicing revision of mutant p53 RNA transcripts 
  • HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. 
  • HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. 
  • Health care costs. 
  • Hematopoietic Stem Cell Gene Therapy with Lentiviral Vector in 4 Patients with Cerebral X-Linked Adrenoleukodystrophy: Long-Term Outcome and Comparison of Efficacy with Allogeneic Hematopoietic Stem Cell Transplantation 
  • Hematopoietic stem cell gene therapy with lentiviral vector in 4 patients with cerebral X-linked adrenoleukodystrophy: long-term outcome and comparison of efficacy with allogeneic hematopoietic stem cell transplantation 
  • Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. 
  • High-Performance Biogas Upgrading Using a Biotrickling Filter and Hydrogenotrophic Methanogens. 
  • High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline. 
  • High-throughput phenotyping of multicellular organisms: finding the link between genotype and phenotype. 
  • Homozygous diploid deletion strains of Saccharomyces cerevisiae that determine lag phase and dehydration tolerance. 
  • Host Transcription Factors and Co-Opted Signaling Pathways Orchestrate Epigenetic Modulation of the AAV Vector Genome 
  • How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. 
  • How eco-evolutionary principles can guide tree breeding and tree biotechnology for enhanced productivity. 
  • Human Pluripotent Stem Cell-Derived Cardiac Tissue Patch for Use in Cell-Based Cardiac Therapy 
  • Human carbonic anhydrase-8 AAV8 gene therapy inhibits nerve growth factor signaling producing prolonged analgesia and anti-hyperalgesia in mice. 
  • Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6 
  • Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis. 
  • Hydrogels for brain repair after stroke: an emerging treatment option 
  • Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. 
  • Hypoxic cell death is reduced by pH buffering in a model of engineered heart tissue. 
  • Identification of a homogentisate-1,2-dioxygenase gene in the fungus Exophiala lecanii-corni: analysis and implications. 
  • Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay. 
  • Identification of fungi associated with municipal compost using DNA-based techniques. 
  • Identifying bioaugmentation candidates for bioremediation of polycyclic aromatic hydrocarbons in contaminated estuarine sediment of the Elizabeth River, VA, USA. 
  • Imaging Biomaterial-Tissue Interactions. 
  • Imaging Trafficking Dynamics of Ultra-Pure Single Adeno-Associated Virus in Live Cells 
  • Imaging of cell/substrate contacts on polymers by total internal reflection fluorescence microscopy. 
  • Immune Reconstitution after Gene Therapy for Adenosine Deaminase Deficient Severe Combined Immune Deficiency (ADA-SCID) 
  • Immunity to Cas9 as an Obstacle to Persistent Genome Editing. 
  • Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. 
  • Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. 
  • Immunomodulatory gene therapy in lysosomal storage disorders. 
  • Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. 
  • Immunotherapeutic targeting of Wilms' tumor protein. 
  • Immunotherapy of cancer with dendritic cell-based vaccines. 
  • Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. 
  • Implications of Gene Therapy for Alzheimer's 
  • Important cellular targets for antimicrobial photodynamic therapy. 
  • Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. 
  • Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. 
  • In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. 
  • In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. 
  • In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA. 
  • In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. 
  • In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using non-primate lentiviral vectors 
  • Increased Frequency of Permanent Integration Following Liver-Directed Gene Therapy with rDNA-AAV2/8 In Murine Phenylketonuria 
  • Increasing the specificity of CRISPR systems with engineered RNA secondary structures. 
  • Inducible regulation of Runx2-stimulated osteogenesis. 
  • Inhalation of an RNA Aptamer Targeting Extracellular Histones Protects from Acute Lung Injury 
  • Inhibition of Caspase-3 Improves Electrotransfer Efficiency and Cell Viability 
  • Inhibition of Extracellular Histones in Sepsis-Induced Cardiovascular Function 
  • Inhibition of barnacle larval settlement and crustacean toxicity of some hoplonemertine pyridyl alkaloids. 
  • Inhibitory activity of probiotics Streptococcus phocae PI80 and Enterococcus faecium MC13 against Vibriosis in shrimp Penaeus monodon 
  • Innovative bioreactors. 
  • Insertional analyses in rhesus monkey blood cells after non-myeloablative hematopoietic stem cell marking with a therapeutic onco-retroviral vector for X-linked chronic granulomatous disease 
  • Integrase-Deficient Lentiviral Vector for Efficient CRISPR/Cas9-Mediated Gene and Epigenome-Editing Applications 
  • Integration of cell-free protein coexpression with an enzyme-linked immunosorbent assay enables rapid analysis of protein-protein interactions directly from DNA. 
  • Integrins Play a Pivotal Role in Transvascular Transport and Tissue Uptake of AAV9 In Vivo 
  • Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. 
  • Intralingual Administration of AAVrh10-miRSOD1 Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis. 
  • Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. 
  • Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I. 
  • Investigation of cell kill in a targeted radiotherapy/gene therapy strategy utilising radiation induced biological bystander effects 
  • Involvement of a Rac1-Dependent Macropinocytosis Pathway in Plasmid DNA Delivery by Electrotransfection. 
  • In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. 
  • Ion channel engineering for modulation and de novo generation of electrical excitability. 
  • Isolation and insecticidal activity of mellamide from Aspergillus melleus. 
  • Isolation of suppressor mutants of phosphatidylinositol 3-phosphate 5-kinase deficient cells in Schizosaccharomyces pombe. 
  • Isolation, growth and differentiation of adult rabbit skeletal myoblasts in vitro 
  • Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. 
  • It's All in the Delivery: Designing Hydrogels for Cell and Non-viral Gene Therapies. 
  • Keeping Sample Preparation Simple: Tips on How to Perform Proteomics Measurements with Consistency and Accuracy 
  • Kinetic studies and unstructured models of lymphocyte metabolism in fed-batch culture. 
  • Large scale purification of factor X by hydrophobic chromatography. 
  • Laser-scanning lithography (LSL) for the soft lithographic patterning of cell-adhesive self-assembled monolayers. 
  • Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae. 
  • Learning from each other: Applying observations from anti-tumor, anti-pathogen and anti-toxin immunotherapy 
  • Lentiviral gene transduction of kidney. 
  • Letter to the Editor: mRNA Vaccines in Urological Malignancies. 
  • Lipid-based Vehicles for siRNA Delivery in Biomedical Field. 
  • Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX gamma 2 in Mice 
  • Liver-Mediated Gene Therapy with an Engineered Secretable GAA Transgene Results in Whole-Body Correction of Pompe Disease 
  • Long-Term Characterization of In Vivo Genome Editing in a Mouse Model of Duchenne Muscular Dystrophy 
  • Long-Term Correction of Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using a Dual Promoter to Express Bacterial Pullulanase 
  • Long-Term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy 
  • Long-Term Evaluation of Genome Editing Outcomes for Duchenne Muscular Dystrophy 
  • Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector. 
  • Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. 
  • Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. 
  • Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. 
  • Loperamide-based compounds as additives for biofouling management 
  • Lymphatic Transport Mediates Systemic Leakage of Peripherally Administered AAV9 Vectors 
  • MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Mapping and Engineering Functional Domains of the Assembly Activating Protein of Adeno-Associated Viruses 
  • Mapping the Antigenic Structure of Adeno-Associated Virus Serotypes 8 and 9 
  • Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. 
  • Mass Spectrometric Identification of Host Factors that Restrict AAV Vector Genome Transcription 
  • Matrix-based gene delivery for tissue repair 
  • Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. 
  • Mechanism of Shortened Bones in Mucopolysaccharidosis VII 
  • Mechanistic Elucidation of Adenovirus Mediated Enhancement of Recombinant Adeno-Associated Virus (rAAV) towards Efficient Low Dose Gene Therapy 
  • Mediator-free amperometric determination of toxic substances based on their inhibition of immobilized horseradish peroxidase. 
  • Medical technologies for the diagnosis of prostate cancer. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. 
  • Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant. 
  • Metabolic regulation of epigenetic remodeling in immune cells. 
  • Metabolomics applied to diabetes research: moving from information to knowledge. 
  • Metalloprotein design. 
  • Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. 
  • Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. 
  • Milligram scale production of potent recombinant small interfering RNAs in Escherichia coli. 
  • Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease. 
  • Modeling of a foamed emulsion bioreactor: I. Model development and experimental validation. 
  • Modeling of a foamed emulsion bioreactor: II. model parametric sensitivity. 
  • Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. 
  • Mold-casted non-degradable, islet macro-encapsulating hydrogel devices for restoration of normoglycemia in diabetic mice. 
  • Molecular cloning and recombinant expression of a gene encoding a fungal immunomodulatory protein from Ganoderma lucidum in Pichia pastoris 
  • Monitoring cellular immune responses to cancer immunotherapy. 
  • Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase. 
  • Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods 
  • Myocardial injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo. 
  • Naked DNA delivered intraportally expresses efficiently in hepatocytes. 
  • Nanopatterned polymer brushes: conformation, fabrication and applications. 
  • Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. 
  • Natural killer cell activation and dendritic cell-based vaccines 
  • Neonatal rAAV2/8 Vector Administration Does Not Prevent Therapeutic Response To Repeat Vector Injection in Adult Pah(enu2/enu2) Mice 
  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. 
  • Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. 
  • Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. 
  • Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector 
  • Novel Gene Supplementation, Genome Editing and Cellular Therapeutic Approaches to Treat Glutaric Aciduria Type I 
  • Novel encapsulation of partially dehydrated protein microparticles in PLGA microspheres 
  • Novel integrase-defective lentiviral episomal vectors for gene transfer. 
  • Nuclear hormone receptors as targets for new drug discovery. 
  • Nucleic acid aptamers as adjuncts to vaccine development. 
  • Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. 
  • Nucleic-Acid Binding Polymers as Anti-Inflammatory Agents 
  • On the road to effective vaccine development 
  • Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. 
  • Oncolytic poliovirus recombinants for the treatment of malignant glioma 
  • Optical nanosensors and biological measurements 
  • Optimization of in vivo crosslinking technique for the study of AlpB-protein interactions in Lysobacter sp. XL1 cells 
  • Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. 
  • Overview of CT technologies for children. 
  • Oxypropylation of cork residues: Preliminary results 
  • PEGDA hydrogels with patterned elasticity: Novel tools for the study of cell response to substrate rigidity. 
  • Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector. 
  • Pain assessment and treatment disparities: a virtual human technology investigation. 
  • Pathogenesis of Growth Failure in Murine and Canine Glycogen Storage Disease-Ia and Partial Reversal of Growth Failure Using Adeno-Associated Viral Vector Therapy 
  • Patient-specific iPSC-derived endothelial cells provide longterm phenotypic correction of hemophilia A 
  • Patterns of regulation from mRNA and protein time series. 
  • Peptide affinity reagents for AAV capsid recognition and purification. 
  • Performance evaluation of a full-scale innovative swine waste-to-energy system. 
  • Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Mycobacterium tuberculosis. 
  • Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors. 
  • Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine. 
  • Personalized health care: from theory to practice. 
  • Personalized medicine: revolutionizing drug discovery and patient care. 
  • Perspectives on the development of anti-HIV vaccines. 
  • Pharmacological regulation of dendritic cell activation: Enhancing cancer vaccine efficacy 
  • Phase 1 Study of Gene Therapy in Late-Onset Pompe Disease: Analyses of Safety and Secondary Endpoints 
  • Phase 1 Study of Gene Therapy in Late-Onset Pompe Disease: Initial 104-Week Experience 
  • Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. 
  • Phase I study of liver depot gene therapy in late-onset Pompe disease. 
  • Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID) 
  • Physical Positioning Dramatically Improves Brain Transduction after Intrathecal Infusion of AAV9 
  • Picoliter DNA sequencing chemistry on an electrowetting-based digital microfluidic platform. 
  • Plant stomata: a checkpoint of host immunity and pathogen virulence. 
  • Plant-centered biosystems in space environments: technological concepts for developing a plant genetic assessment and control system. 
  • Policies and Pitfalls: What the Alzheimer's Community Can Learn from the Deployment of Disease-Modifying Therapies for Multiple Sclerosis Patients 
  • Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells. 
  • Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. 
  • Potentially functional genetic variants of VAV2 and PSMA4 in the immune-activation pathway and non-small cell lung cancer survival. 
  • Potentially functional genetic variants of the notch signaling pathway genes predict survival of Chinese patients with esophageal squamous cell carcinoma. 
  • Powerful ideas driven by simple tools: lessons from experimental embryology. 
  • Pre-Existing Humoral Immunity to AAV Capsids: Species and Age-Related Differences in Anti-Capsid ELISA and Neutralizing Antibody Assays 
  • Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. 
  • Preclinical Development of New Therapy for Glycogen Storage Diseases. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Predation of bacteria by the protozoa Tetrahymena pyriformis in toluene-degrading cultures 
  • Preface 
  • Prenatal gene tranfer: scientific, medical, and ethical issues: a report of the Recombinant DNA Advisory Committee. 
  • Preparation and activity of carbonic anhydrase immobilized on porous silica beads and graphite rods. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Prevalence and patterns of Transmitted Drug Resistance in HIV-Infected Adult Patients Initiating Antiretroviral Therapy in Hanoi, Vietnam 
  • Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. 
  • Priming, boosting, measuring. 
  • Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. 
  • Programming microbial population dynamics by engineered cell-cell communication. 
  • Properties affecting transfer and expression of degradative plasmids for the purpose of bioremediation. 
  • Prostate cancer: status of current treatments and emerging antisense-based therapies. 
  • Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: A strategy for broad clinical application 
  • Protein engineering and the development of generic biosensors. 
  • Protein engineering approaches to biomaterials design. 
  • Protein patterning. 
  • Protein purification by fusion with an environmentally responsive elastin-like polypeptide: effect of polypeptide length on the purification of thioredoxin. 
  • Proteolytically degradable hydrogels with a fluorogenic substrate for studies of cellular proteolytic activity and migration. 
  • Proteomics for monitoring immune responses to cancer vaccines. 
  • Proximity labeling of endogenous protein interactions enabled by directed evolution. 
  • Purification of an elastin-like fusion protein by microfiltration. 
  • Quantitation of cell area on glass and fibronectin-coated surfaces by digital image analysis. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma 
  • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
  • RNA repair as a novel approach to genetic therapy. 
  • RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors. 
  • RNF121 is a Key Transcriptional Regulator of AAV Genome Expression 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Re-Engineering Capsid-Glycan Interactions Expands the CNS Transduction Profile of AAV Serotype 4 
  • Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. 
  • Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Recombinant DNA Advisory Committee. Department of Health and Human Services. National Institutes of Health. Minutes of meeting. December 15-16, 1997. 
  • Recombinant DNA Advisory Committee. Department of Health and Human Services. National Institutes of Health. Minutes of meeting. March 10, 1998. 
  • Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. 
  • Recovery of pyruvic acid from biotransformation solutions. 
  • Recruitment of bloom-forming cyanobacteria and its driving factors 
  • Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. 
  • Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy. 
  • Reduction of invasive bacteria in ethanol fermentations using bacteriophages. 
  • Regional-CNS MiniPromoters for AAV Are Identified in a High Through-Put Pipeline 
  • Regulation of plant root system architecture: implications for crop advancement. 
  • Relative gene expression quantification in a fungal gas-phase biofilter. 
  • Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. 
  • Reporting Long Term Survival Following Precision Tumor-Targeted Gene Delivery to Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone 
  • Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia. 
  • Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. 
  • Respiratory Directed Gene Therapy to Silence SOD1 Prolongs Survival in the SOD1 ALS Mouse 
  • Response to Goldman and Brown: Making sense of microbial consortia using ecology and evolution 
  • Responsible Use of Human Gene-Editing Technologies. 
  • Results of One Year Follow-Up After Treatment With Fordadistrogene Movaparvovec (PF-06939926) for Duchenne Muscular Dystrophy (DMD) in A Phase 1b, Open-label Study 
  • Retargeting mobile group II introns to repair mutant genes. 
  • Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-β? 
  • Review: Tissue engineering in the nervous system 
  • Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. 
  • Rich before old? 
  • Rna Inhibitors of Nuclear Proteins Implicated in Multiple Organ Dysfunction Syndrome 
  • Role of Vp2 in AAV packaging 
  • Role of pericellular matrix in development of a mechanically functional neocartilage. 
  • Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro. 
  • STRV5, a Liver Detargeted AAV Capsid Demonstrates Improved Safety Profile After Intravenous Administration of High Doses in Non-Human Primates 
  • Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. 
  • Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. 
  • Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease. 
  • Salmeterol with Liver Depot Gene Therapy Reversed Biochemical and Autophagic Abnormalities of Skeletal Muscle in Pompe Disease 
  • Salmeterol, a Beta-Agonist, Enhances Therapeutic Efficacy in Pompe Gene Therapy 
  • Science and the law. Working through the patent problem. 
  • Selective modification of antigen-specific T cells by RNA electroporation. 
  • Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. 
  • Serial real-time luminescence imaging profiles differential kinetics and biodistibution of transgene expression from AAV serotype 1-5 vectors following adult and neonatal gene transfer 
  • Shear degradation as a probe of microalgal exopolymer structure and rheological properties 
  • Short-term cell/substrate contact dynamics of subconfluent endothelial cells following exposure to laminar flow. 
  • Sialic Acids and Erythrocyte Interactions Are Critical Determinants of Cardiopulmonary Tropism Displayed by AAV Serotype 4 
  • Signal-transduction cascades as targets for therapeutic intervention by natural products. 
  • Single Vector AAV Approach to Genome Editing in Pompe Disease 
  • Single- and dual-fractal analysis of hybridization binding kinetics: biosensor applications. 
  • Smooth Muscle Cell Targeted RNA Aptamers for the Treatment of Vascular Disease 
  • Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. 
  • Solubilization of tricalcium phosphate by P(3HB) accumulating Azotobacter chroococcum MAL-201. 
  • Split luciferase complementation assay for the analysis of G protein-coupled receptor ligand response in Saccharomyces cerevisiae. 
  • Spontaneous bacterial cell lysis and biofilm formation in the colon of the Cape Dune mole-rat and the laboratory rabbit. 
  • Stabilization of D-amino acid oxidase and catalase in permeabilized Rhodotorula gracilis cells and its application for the preparation of alpha-ketoacids*. 
  • Statistical determination of steady state condition in bioremediation tests 
  • Steady ongoing hematological and immunological reconstitution achieved in ADA-deficiency patients treated by stem cell gene therapy with no myelopreparative conditioning 
  • Stimulus responsive elastin biopolymers: Applications in medicine and biotechnology. 
  • Streptavidin-biotin binding energetics. 
  • Structural Mapping of AAV9 Antigenic Sites and the Engineering of Immune Escape Variants 
  • Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice 
  • Structure-Guided Iterative Evolution of Antigenically Advanced AAV Variants for Therapeutic Gene Transfer 
  • Studies on the preparation of chitosan microcarriers cross-linked by oxidized lactose and culture of primary hepatocytes. 
  • Study of substrate specificity of RNR-exoribonucelases using hybrid proteins 
  • Subgenomic Flaviviral RNA Elements Enhance rAAV Vector mRNA Stability and Transduction 
  • Substrate (gelatin) gel electrophoretic method for analysis of protease activity in insect (Sf-9) cells 
  • Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease. 
  • Successful immunization with a single injection of non-integrating lentiviral vector. 
  • Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. 
  • Synchronous luminescence: A simple technique for the analysis of hydrolysis activity of the fragile histidine triad protein 
  • Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. 
  • Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors 
  • Synergistic effect of shear stress and streptavidin-biotin on the expression of endothelial vasodilator and cytoskeleton genes. 
  • Synthetic Biology: Caught Between Property Rights, the Public Domain, and the Commons 
  • Synthetic Biology: Reports from CSHA 2016 and More. 
  • Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy. 
  • Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease. 
  • Systemic Delivery of AAVB1-GAA Gene Therapy for Respiratory Pathology in Pompe Disease 
  • Systemic Expression of Translatable Circular Rnas Using Recombinant AAV Vectors 
  • Systemic and Persistent Muscle Gene Expression in Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector. 
  • Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts. 
  • Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant 
  • Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. 
  • Targeting Muscle Satellite Cells for In Vivo Gene Editing With Adeno-Associated Viral Vectors for Duchenne Muscular Dystrophy 
  • Technology developments in endovascular treatment of intracranial aneurysms. 
  • Technology evaluation: BLP-25, Biomira Inc. 
  • Technology evaluation: CEA-TRICOM, Therion Biologics Corp. 
  • Technology evaluation: ISIS-2503, Isis Pharmaceuticals. 
  • Technology evaluation: Rexin-G, Epeius Biotechnologies. 
  • Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc. 
  • Technology evaluation: Theratope, Biomira Inc. 
  • Technology evaluation: VEGF165 gene therapy, Valentis Inc. 
  • Technology evaluation: gene therapy (IL-2), Valentis Inc. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. 
  • The AAV vector toolkit: poised at the clinical crossroads. 
  • The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition 
  • The Human Silencing Hub (HUSH Complex) Is a Potent Regulator of AAV Transgene Silencing 
  • The Image Gently ALARA CT summit on new CT technologies for children. 
  • The Membrane-Associated Accessory Protein (MAAP) is Essential for Rapid Extracellular Secretion of Adeno-Associated Viruses 
  • The New Epigenome-Editing Approach for Targeting Dysregulated SNCA Expression: Novel Target Validation for Next-Generation Drug Discovery 
  • The New Frontier in the Development of LOAD Therapies Targeting APOE 
  • The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. 
  • The Removal of Volatile Ketone Mixtures from Air in Biofilters 
  • The U.S. Culture Collection Network Responding to the Requirements of the Nagoya Protocol on Access and Benefit Sharing 
  • The development of new biotechnologies using metalloprotein design. 
  • The development of optical nanosensors for biological measurements. 
  • The early years of single photon emission computed tomography (SPECT): an anthology of selected reminiscences. 
  • The effect of an applied potential on the activity of carbonic anhydrase immobilized on graphite rods. 
  • The effect of osmotic stress on the production of nukacin ISK-1 from Staphylococcus warneri ISK-1. 
  • The effect of packing hydrophilization on bacterial attachment and the relationship with the performance of biotrickling filters. 
  • The impact of genomics on the biotechnology industry. 
  • The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. 
  • The quantity and quality of worldwide new drug introductions, 1982-2003. 
  • The rational design of allosteric interactions in a monomeric protein and its applications to the construction of biosensors. 
  • The removal of volatile ketone mixtures from air in biofilters 
  • The role of single-cell analyses in understanding cell lineage commitment. 
  • The synthetic utility of KDPGal aldolase 
  • The transcapsidation of AAV serotypes 
  • Therapeutic Benefit of Autophagy Modulation in Pompe Disease. 
  • Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. 
  • Time-Dependent Changes in ON Bipolar Cell Transcriptomes before and after Genetic Rescue from Rod Degeneration 
  • Tissue Engineered Human Skeletal Muscle as a Pre-Clinical Model for AAV Treatment of Pompe Disease 
  • Tissue engineering of functional skeletal muscle: challenges and recent advances. 
  • Toluene degradation in the recycle liquid of biotrickling filters for air pollution control. 
  • Total RNA isolation by a rapid centrifugation method. 
  • Toward predictive engineering of gene circuits. 
  • Training physicians for careers in clinical research: a tailored educational experience. 
  • Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. 
  • Transcriptional regulation improves the throughput of three-hybrid counter selections in Saccharomyces cerevisiae. 
  • Transcriptional regulation of changes in growth, cell cycle, and gene expression of Saccharomyces cerevisiae due to changes in buoyancy. 
  • Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transgene Immunogenicity Has Significant Effects on Gene Therapy in a Mouse Model of Adult Polyglucosan Body Disease 
  • Transient-state behavior of a biofilter removing mixtures of vapors of MEK and MIBK from air. 
  • Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. 
  • Transmembrane transport of marker molecules and cell membrane kinetics during electropermeabilization 
  • Treatment of Sepsis by Neutralization of Extracellular Histones with Nucleic Acid Aptamers 
  • Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. 
  • Turning lemons into lemonade: learning from negative studies in cancer immunotherapy. 
  • U.S. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee: Minutes of meeting: December 6, 2001 
  • Ultra-high expression of a thermally responsive recombinant fusion protein in E. coli. 
  • Uncertain benefit: investigators' views and communications in early phase gene transfer trials. 
  • Understanding metabolism with flux analysis: From theory to application. 
  • Underwater life support based on immobilized oxygen carriers. 
  • Universal purification of AAV serotypes 1-5 modified to contain a heparin binding epitope 
  • Unlocking Avian AAV Transduction in Mammalian Cells and Tissues for Immune Evasion and Redosing 
  • Use of Sepharose 4B for preparative scale fractionation of eukaryotic messenger RNA's. 
  • Using Functional SNPs to Calculate a Polygenic Risk Score for LOAD 
  • VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. 
  • VSMC Specific Aptamer Ligands for the Next Generation of DES to Prevent Neointimal Formation 
  • Validation of therapeutic strategies in a novel compound heterozygote model of Methylmalonic Acidemia 
  • Vector Genome Length and Self-Complementarity Affect AAV Capsid Uncoating 
  • Vector-related tumorigenesis not found in ornithine transcarbamylase-deficient mice. 
  • Viral vector gene delivery of the novel chaperone protein SRCP1 to modify insoluble protein in in vitro and in vivo models of ALS. 
  • Viruses for the treatment of malignant glioma. 
  • When is an adjuvant not an adjuvant? 
  • When is an adjuvant not an adjuvant? Overview. 
  • Whole-body correction of Pompe disease by AAV liver-mediated gene transfer of engineered secretable GAA transgenes 
  • Wide Spread Adenoviral Vector Delivery to a Cardiac Allograft Utilizing an Ex Vivo Perfusion Storage Strategy 
  • Wolfgang Barz [formula omitted] Coństitutive and Elicitation Induced Metabolism of Isoflavones and Pterocarpans in Chickpea (Cicer arietinum) Cell Suspension Cultures 
  • X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. 
  • X-ray crystallographic studies of streptavidin mutants binding to biotin. 
  • ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. 
  • Zero incidence of adeno-associated virus serotype 9 (AAV9) antibodies in a cohort of spinal muscular atrophy (SMA) type 1 patients screened in STR1VE, a pivotal phase 3 study of AVXS-101 
  • β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes. 
• 

  Keywords of People

  • Huang, Linfeng, Associate Professor of Biology at Duke Kunshan University, DKU Faculty
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Ridley, David Blaine, Professor of the Practice of Business Administration, Duke Science & Society
  • Sexton, Steven E., Mark and Lynne Florian Associate Professor of Public Policy, Economics